Investigation Report on China Repaglinide Market, 2010-2019

Publisher Name :
Date: 02-Jul-2015
No. of pages: 30

According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.

There are about 90 million diabetes patients in today's China and 95% of them suffer from type 2 diabetes mellitus. And the number of potential patients might reach up to 200 million.??

Entering China after 2000, insulin secretagogues agent is mainly used for the treatment of type 2 diabetes. Currently, there are only 3 kinds available in the Chinese market, namely, nateglinide, repaglinide and mitiglinide. They share the same mechanism of action, that is to say, they lower blood glucose by stimulating the release of insulin from the beta cells. Compared with sulfonylurea, insulin secretagogues agent reports shorter duration of glucoselowering action and lower rate of hypoglycemia.

As an insulin secretagogues agent structured different from sulfonylurea, repaglinide is used to control postprandial hyperglycemia. Developed by Novo Nordisk A/S and BoehringerIngelheim together, it entered the United States in Apr. 1998.

As the first new prandial glucose regulator, repaglinide belongs to the class of benzoic acid derivative. Containing a chiral carbon atom, it has stereoselective activity and can be absorbed well on an empty stomach or not. As repaglinide is expelled from the body with bile after being metabolized by CYP3A4 enzyme system in the liver and only 6% of it is excreted through kidney, it is more suitable for patients with kidney disorders. Hence its advantage in the clinic. In 2000, repaglinide of Novo Nordisk A/S came to be sold in China under the name of Novonorm. According to CRI's market survey, it has few rivals and takes up a market share of about 89% for sales value while its main competitor Hanson Pharmaceutical only occupies less than 11% of the market. The sales value of repaglinide in sample hospitals was about CNY 125 million in 2014 and CAGR during the period of 20052014 reached about 22%.

The market size of repaglinide is expected to keep growing in the next few years in China.

Readers can get at least the following information through this report:


  • market size of repaglinide in China

  • major manufacturers of repaglinide for Chinese market and their market share

  • retail price of repaglinide in Chinese market

  • market outlook of repaglinide in China


The author suggests the following groups of people purchase this report:


  • manufacturers of antidiabetic drugs

  • investors/ research institutions interested in Chinese medicine market

  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Investigation Report on China Repaglinide Market, 2010-2019

Table of Contents

1 Related Concepts of Repaglinide
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Repaglinide in China
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Repaglinide in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Manufacturers of Repaglinide in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Dosage Forms of Repaglinide in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Price of Repaglinide in Chinese Hospitals in 2014
6.1 Novo Nordisk A/S (Denmark)
6.2 Hanson Pharmaceutical
6.3 Tianjin Kangrui Pharmaceutical Co., Ltd
6.4 Beijing Wansheng Pharmaceutical Co., Ltd

7 Major Manufacturers of Repaglinide in Chinese Market, 2010-2014
7.1 Novo Nordisk A/S (Denmark)
7.2 Hanson Pharmaceutical
7.3 Tianjin Kangrui Pharmaceutical Co., Ltd
7.4 Beijing Wansheng Pharmaceutical Co., Ltd

8 Market Outlook of Repaglinide in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

List of Charts

Chart Patent Registration Information of Repaglinide in China
Chart Approval Status of Repaglinide in China
Chart Sales Status of Repaglinide in China, 2010-2014
Chart Sales Value of Repaglinide in China, 2010-2014
Chart Sales Value of Repaglinide by Regions in China, 2010-2014
Chart Sales Value of Repaglinide Tablets in China, 2010-2014
Chart Sales Value of Repaglinide Capsules in China, 2010-2014
Chart Market Share of Major Manufacturers of Repaglinide for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Repaglinide Made by Novo Nordisk A/S, 2010-2014
Chart Sales Value and Market Share of Repaglinide Made by Hanson Pharmaceutical, 2010-2014
Chart Sales Value and Market Share of Repaglinide Made by Tianjin Kangrui Pharmaceutical Co., Ltd, 2010-2014
Chart Price of Repaglinide Made by Novo Nordisk A/S in Some Chinese Cities in 2014
Chart Price of Repaglinide Made by Hanson Pharmaceutical in Some Chinese Cities in 2014
Chart Price of Repaglinide Made by Tianjin Kangrui Pharmaceutical Co., Ltd in Some Chinese Cities in 2014

  • United States Metformin Hydrochloride Market Report 2017
    Published: 19-Sep-2017        Price: US 3800 Onwards        Pages: 112
    In this report, the United States Metformin Hydrochloride market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth ......
  • United States Glucagon Like Peptide-1 (GLP-1) Agonists Market Report 2017
    Published: 19-Sep-2017        Price: US 3800 Onwards        Pages: 102
    In this report, the United States Glucagon like peptide-1 (GLP-1) agonists market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market ......
  • Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Report 2017
    Published: 15-Sep-2017        Price: US 4000 Onwards        Pages: 106
    In this report, the global Glucagon like peptide-1 (GLP-1) agonists market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Glucagon like peptide-1 (GLP-1) agonists for these regions, from 2012 to 2022 (forecast), covering - United States......
  • Global Metformin Hydrochloride Sales Market Report 2017
    Published: 15-Sep-2017        Price: US 4000 Onwards        Pages: 111
    In this report, the global Metformin Hydrochloride market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Metformin Hydrochloride for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe ......
  • United States Incretin-Based Drugs Market Report 2017
    Published: 07-Sep-2017        Price: US 3800 Onwards        Pages: 103
    In this report, the United States Incretin-Based Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rat......
  • United States Acarbose Market Report 2017
    Published: 05-Sep-2017        Price: US 3800 Onwards        Pages: 107
    In this report, the United States Acarbose market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of......
  • Global Antidiabetics Drug Market Professional Survey Report 2017
    Published: 05-Sep-2017        Price: US 3500 Onwards        Pages: 108
    This report studies Antidiabetics Drug in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - AstraZeneca - Bayer - Boehringer Ingelheim - Eli-Lilly - J......
  • Global Incretin-Based Drugs Sales Market Report 2017
    Published: 04-Sep-2017        Price: US 4000 Onwards        Pages: 100
    In this report, the global Incretin-Based Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (MT), revenue (Million USD), market share and growth rate of Incretin-Based Drugs for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan......
  • Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Research Report 2017
    Published: 01-Sep-2017        Price: US 2900 Onwards        Pages: 100
    In this report, the global Glucagon like peptide-1 (GLP-1) agonists market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Glucagon like peptide-1 (GLP-1) agonists in these regions, from 2012 to 2022 (forecast), covering - North A......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs